Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab.

NCT07151508 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.

NCT NCT07151508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Successful Treatment of Netherton Syndrome With Combination of Secukinumab and Dupilumab.
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase
Observational
Overall status
Completed
Start date
December 19, 2023
Completion date
January 10, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neterton syndrome